TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04230226

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre-workout plus and protein recovery plus
Description: Study products consumed prior and after exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product consumed prior and after exercise
Study: NCT00938210

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Laparoscopic colonic surgery
Description: Laparoscopic removal of colonic cancer
Study: NCT01567956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propionyl-L-Carnitine
Description: 500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
Study: NCT03708211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931 PIC
Description: TAK-931 PICs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931 PIC
Description: TAK-931 PICs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931 Tablet
Description: TAK-931 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931 Tablet
Description: TAK-931 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931 Tablet
Description: TAK-931 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931 Tablet
Description: TAK-931 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole Tablets.
Study: NCT01975805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone Iodine
Study: NCT03059862

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-tryptophan
Description: 3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
Study: NCT03839706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET MRI
Description: 18F-Fluorodeoxyglucose Positron Emission Tomography combined with Primovist MRI
Study: NCT00097695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: 30 mg (3mL) subcutaneous icatibant injection in the abdominal region

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: 30 mg (3mL) subcutaneous icatibant injection in the abdominal region

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: 30 mg (3mL) subcutaneous icatibant injection in the abdominal region

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection, matched to study drug Single dose: 3 mL
Study: NCT02689908

Intervention type: RADIATION
Group type: OTHER
Intervention: computed tomography
Description: low dose protocol of thorax ct
Study: NCT01124149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMX mesalamine/ mesalazine
Description: 4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months
Study: NCT03236857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Oral tablet for participants; Tablet for oral suspension (participants who cannot swallow a tablet)
Study: NCT00169533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW572016 oral tablets
Description: Lapatinib either at 750, 1000, 1250 or 1500 mgs
Study: NCT04091347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DAPPER
Description: The DAPPER program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DAPPER
Description: The DAPPER program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.
Study: NCT00995553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: This is an adaptive, computer-based cognitive training intervention. Participants will complete 3 1-hour cognitive training sessions focused on attention and working memory processes weekly for 4 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer Skills
Description: This is a computer-based course in which participants will be taught how to use Microsoft Office applications and typing skills. Participants will attend a 1-hour course three times a week four 4-months.
Study: NCT01226069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerine Magnesium sulphate paste
Description: Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mucopolysaccharide polysulphate
Description: Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No application
Description: No application
Study: NCT00788125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03006016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acid
Description: The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
Study: NCT03715270

Intervention type: DEVICE
Intervention: Image surgical area
Description: Image surgical area
Study: NCT03427970

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: observation
Description: Control group will receive the standard of care according to the Scoliosis Research Society criteria: observation for patients with curves between 10°- 25°.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: three-dimensionally integrated exercise for scoliosis
Description: Experimental group will receive a modified physiotherapeutic scoliosis specific exercises --the three-dimensionally integrated exercise for scoliosis program, which include auto-correction in 3D, postural correction, breathing training, resistance training, muscle fascia releasing, functional activities, balance training, core stability training, proprioceptive input exercises and patient education. Auto-correction exercise in 3D will combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.
Study: NCT02152878

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: For sham tDCS, the device will be turned off after 30 seconds of stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active stimulation
Description: For active tDCS, we will place the anode and the cathode over the left and right dorsolateral prefrontal cortex areas, respectively (corresponding to F3 and F4 according to the EEG 10-20 system). We will use 5x5 cm electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup and has been previously used in major depression trials
Study: NCT00991848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: received 240 mg lidocaine diluted in 125 mL 0.9% saline.
Study: NCT02596503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.
Study: NCT01459874

Intervention type: BEHAVIORAL
Intervention: Organizational model for remote monitoring
Description: An organizational model defining roles and behaviors of subjects involved in the remote monitoring of pacemaker and defibrillator recipients
Study: NCT01706926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 30 mg
Description: Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg
Description: Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 150 mg
Description: Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.
Study: NCT02287532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABEO software
Description: DIABEO is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system. DIABEO software could be combined with remote paramedical monitoring of data (telemonitoring)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABEO software
Description: DIABEO is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system. DIABEO software could be combined with remote paramedical monitoring of data (telemonitoring)
Study: NCT01779622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal
Description: Ingestion of mixed meal
Study: NCT03328793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood Assessment
Description: Prior to and after the session, the patients will be asked to fill a VAMS (Visual Analog Mood Scale).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood Assessment
Description: Prior to and after the session, the patients will be asked to fill a VAMS (Visual Analog Mood Scale).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion Assessment
Description: During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the Observed Emotional Rating Scale (OERS), the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Assessment
Description: During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the Observed Emotional Rating Scale (OERS), the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication Assessment
Description: During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the CODEM Scale, the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Assessment
Description: During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the CODEM Scale, the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobility assessment
Description: If deemed to be safe, the patients will undergo a gait speed assessment as well as a TUG (timed-up-and-go) prior to and after the sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobility assessment
Description: If deemed to be safe, the patients will undergo a gait speed assessment as well as a TUG (timed-up-and-go) prior to and after the sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: The participants will listen to a 30 minute live music sessions which will be given by musicians (who is a volunteer)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Documentary watching
Description: The patients will watch a documentary for 30 minutes in the presence of a volunteer
Study: NCT00922909

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simon task
Description: Reaction time task

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simon task
Description: Reaction time task

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simon task
Description: Reaction time task

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Simon task
Description: Reaction time task
Study: NCT01220830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytotron
Description: Exposure to RFQMR with Cytotron for 28 consecutive days for one hour daily.
Study: NCT03248063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cloxacillin
Description: Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion. This treatment will be administered for at least 7 days by intravenous route.~Dosing regimen will be adapted in patients with chronic renal failure (glomerular filtration rate below 30ml/min/1.73m²) and in patient with impaired hepatic function associated with renal impairment whatever the level of the estimation of the glomerular filtration rate, according to SPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion. This treatment will be administered for 14 days by intravenous route. Dosing regimen will be adapted in case of glomerular filtration rate between 30-50ml/min according to SPC. As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.
Study: NCT04439656

Intervention type: DIAGNOSTIC_TEST
Intervention: Eye movement analysis
Description: Eye movements will be analyzed to identify if seizures are present and compared to the EEG read
Study: NCT02037997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel 75mg/m2 ivgtt D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: docetaxel 75mg/m2 ivgtt D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500mg/m2 ivgtt D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: pemetrexed 500mg/m2 ivgtt D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150mg qd
Study: NCT04809675

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hard occlusal splint
Description: Use of a hard occlusal splint at times they considered helpful.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hard occlusal splint
Description: Use of a hard occlusal splint at times they considered helpful.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible customized mouthguard
Description: Use of a flexible customized mouthguard at times they considered helpful.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible customized mouthguard
Description: Use of a flexible customized mouthguard at times they considered helpful.
Study: NCT04194866

Intervention type: OTHER
Group type: OTHER
Intervention: receiving operation during the day or at night
Description: 120 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and in the Night Group (18:00-22:00)

Intervention type: OTHER
Group type: OTHER
Intervention: receiving operation during the day or at night
Description: 120 patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and in the Night Group (18:00-22:00)
Study: NCT04905433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation with breathing retraining
Description: A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling), with a breathing retraining (using breathing calisthenics, and inspiratory muscle training)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: A cardiac rehabilitation program for 3 days/week (day after day) for 12 weeks(including aerobic, and resisted exercise, with educational sessions, and counseling) only
Study: NCT01722981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous tracheostomy
Description: Three methods of percutaneous tracheostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous tracheostomy
Description: Three methods of percutaneous tracheostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous tracheostomy
Description: Three methods of percutaneous tracheostomy
Study: NCT00620763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Meat - High Potential Renal Acid Load (PRAL) diet
Description: Menu high in meat protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Meat - High Potential Renal Acid Load (PRAL) diet
Description: Menu high in meat protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein - Low Potential Renal Acid Load (PRAL) diet
Description: Menu low in meat protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein - Low Potential Renal Acid Load (PRAL) diet
Description: Menu low in meat protein
Study: NCT00560235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity